The main approaches to the prevention of viral hepatitis A

O.V. Oniskova, L.O. Yushchenko, V.О. Tikholaz, V.S. Oleynik, O.O. Gordiychuk, T.V. Malanina


Currently, the prevention of hepatitis A in populations with the intermediate level of endemicity is a significant issue. Vaccination associated with the importance of environmental and personal hygiene and sanitation are the most effective methods of prophylaxis in the world. Hepatitis A vaccination provides long-term protective effects, it is well tole­rated and has less side effects. The possibility of hepatitis A vaccination should be considered, especially in the risk groups of populations with the intermediate level of endemicity for hepatitis A.


viral hepatitis A; vaccination; vaccine schedules; prevention


Franco E, Meleleo C, Serino L, Sorbara D, Zaratti L. Hepatitis A: Epidemiology and prevention in developing countries. World J Hepatol. 2012 Mar 27;4(3):68-73. doi: 10.4254/wjh.v4.i3.68.

WHO position paper on hepatitis A vaccines: June 2012-recommendations. Vaccine. 2013 Jan 2;31(2):285-6. doi: 10.1016/j.vaccine.2012.10.102.

Lin KY, Chen GJ, Lee YL, et al. Hepatitis A virus infection and hepatitis A vaccination in human immunodeficiency virus-positive patients: A review. World J Gastroenterol. 2017 May 28;23(20):3589-3606. doi: 10.3748/wjg.v23.i20.3589.

Matheny SC, Kingery JE. Hepatitis A. Am Fam Physician. 2012 Dec 1;86(11):1027-34; quiz 1010-2.

Aasheim ET, Seymour M, Balogun K, Ngui SL, Williams CJ, Shankar AG. Acute hepatitis A in an elderly patient after care worker travel to high endemicity country. Hum Vaccin Immunother. 2013 Nov;9(11):2480-2. doi: 10.4161/hv.25719.

Dugo V, Zaratti L, Mita V, Franco E. Update of recommendations for the prevention of Hepatitis A in Italy. Ig Sanita Pubbl. 2014 Jul-Aug;70(4):431-41. (in Italian).

Advisory Committee on Immunization Practices (ACIP) Centers for Disease Control and Prevention (CDC). Update: Prevention of hepatitis A after exposure to hepatitis A virus and in international travelers. Updated recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Morb Mortal Wkly Rep. 2007 Oct 19;56(41):1080-1084.

World Health Organization. International travel and health: situation as on 1 January 2012. Geneva: WHO-press; 2012. 265 p.

State Expert Center of the Ministry of Health of Ukraine. Travel Vaccination Guidelines. Available from: .

Nelson NP. Hepatitis A. In: Centers for Diseases Control and Prevention (CDC). CDC Health Information for International Travel 2018. Chapter 3. Infectious Diseases Related to Travel. Available from: . Accessed: September 29, 2017.

Markus JR, Cruz CR, Maluf EM, Tahan TT, Hoffmann MM. Seroprevalence of hepatitis A in children and adolescents. J Pediatr (Rio J). 2011 Sep-Oct;87(5):419-24. doi: 10.2223/JPED.2119.

Murphy TV, Denniston MM, Hill HA, et al. Progress Toward Eliminating Hepatitis A Disease in the United States. MMWR Suppl. 2016 Feb 12;65(1):29-41. doi: 10.15585/mmwr.su6501a6.

Peetermans J. Production, quality control and characterization of an inactivated hepatitis A vaccine. Vaccine. 1992;10 Suppl 1:S99-101.

Ott JJ, Irving G, Wiersma ST. Long-term protective effects of hepatitis A vaccines. A systematic review. Vaccine. 2012 Dec 17;31(1):3-11. doi: 10.1016/j.vaccine.2012.04.104.

Academy of Pediatrics Committee on Infectious Diseases. Hepatitis A vaccine recommendations. Pediatrics. 2007 Jul;120(1):189-99. doi: 10.1542/peds.2007-1088.

Van Damme P, Van Herck K. A review of the efficacy, immunogenicity and tolerability of a combined hepatitis A and B vaccine. Expert Rev Vaccines. 2004 Jun;3(3):249-67. doi: 10.1586/14760584.3.3.249.

Beran J. Bivalent inactivated hepatitis A and recombinant hepatitis B vaccine. Expert Rev Vaccines. 2007 Dec;6(6):891-902. doi: 10.1586/14760584.6.6.891.

Hens N, Habteab Ghebretinsae A, Hardt K, Van Damme P, Van Herck K. Model based estimates of long-term persistence of inactivated hepatitis A vaccine-induced antibodies in adults. Vaccine. 2014 Mar 14;32(13):1507-13. doi: 10.1016/j.vaccine.2013.10.088.

Garcia Garrido HM, Wieten RW, Grobusch MP, Goorhuis A. Response to Hepatitis A Vaccination in Immunocompromised Travelers. J Infect Dis. 2015 Aug 1;212(3):378-85. doi: 10.1093/infdis/jiv060.

Askling HH, Rombo L, van Vollenhoven R, et al. Hepatitis A vaccine for immunosuppressed patients with rheumatoid arthritis: a prospective, open-label, multi-centre study. Travel Med Infect Dis. 2014 Mar-Apr;12(2):134-42. doi: 10.1016/j.tmaid.2014.01.005.

Crum-Cianflone NF, Wilkins K, Lee AW, et al. Long-term durability of immune responses after hepatitis A vaccination among HIV-infected adults. J Infect Dis. 2011 Jun 15;203(12):1815-23. doi: 10.1093/infdis/jir180.

Crisinel PA, Posfay-Barbe KM, Aebi C, et al. Determinants of hepatitis A vaccine immunity in a cohort of human immunodeficiency virus-infected children living in Switzerland. Clin Vaccine Immunol. 2012 Nov;19(11):1751-7. doi: 10.1128/CVI.00264-12.

Jimenez HR, Hallit RR, Debari VA, Slim J. Hepatitis A vaccine response in HIV-infected patients: are TWINRIX and HAVRIX interchangeable? Vaccine. 2013 Feb 18;31(9):1328-33. doi: 10.1016/j.vaccine.2012.12.045.

Cui F, Liang X, Wang F, Zheng H, Hutin YJ, Yang W. Development, production, and postmarketing surveillance of hepatitis A vaccines in China. J Epidemiol. 2014;24(3):169-77. doi:10.2188 / jea.JE20130022.

Mitra M, Shah N, Faridi M, et al. Long term follow-up study to evaluate immunogenicity and safety of a single dose of live attenuated hepatitis a vaccine in children. Hum Vaccin Immunother. 2015;11(5):1147-52. doi: 10.4161/21645515.2014.979646.

Rao S, Mao JS, Motlekar S, Fangcheng Z, Kadhe G. A review of immunogenicity and tolerability of live attenuated Hepatitis A vaccine in children. Hum Vaccin Immunother. 2016 Dec;12(12):3160-3165. doi: 10.1080/21645515.2016.1216286.

Zheng H, Chen Y, Wang F, et al. Comparing live attenuated and inactivated hepatitis A vaccines: an immunogenicity study after one single dose. Vaccine. 2011 Nov 8;29(48):9098-103. doi: 10.1016/j.vaccine.2011.08.078.

Zhang Z, Zhu X, Hu Y, et al. Five-year antibody persistence in children after one dose of inactivated or live attenuated hepatitis A vaccine. Vaccine. 2011 Nov 8;29(48):9098-103. doi: 10.1016/j.vaccine.2011.08.078.

Stuurman AL, Marano C, Bunge EM, De Moerlooze L, Shouval D. Impact of universal mass vaccination with monovalent inactivated hepatitis A vaccines - A systematic review. Hum Vaccin Immunother. 2017 Mar 4;13(3):724-736. doi: 10.1080/21645515.2016.1242539.

Aggarwal R, Goel A. Hepatitis A: epidemiology in resource-poor countries. Curr Opin Infect Dis. 2015 Oct;28(5):488-96. doi: 10.1097/QCO.0000000000000188.

Nelson NP, Allison MA, Lindley MC, et al. Physician knowledge and attitudes about Hepatitis A and current practices regarding hepatitis a vaccination delivery. Acad Pediatr. 2017 Jul;17(5):562-570. doi: 10.1016/j.acap.2017.01.001.

Copyright (c) 2019 GASTROENTEROLOGY

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.


© Publishing House Zaslavsky, 1997-2019


   Seo анализ сайта